Immunome Research

Immunome Research
Open Access

ISSN: 1745-7580

+32-2-808-66-58

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Linglong Zou

Linglong Zou

Linglong Zou
Director, Experimental Immunology Global Bioassays and Technology
Teva Pharmaceuticals, USA

Biography

Linglong Zou is currently the Director of Experimental Immunology in Teva Pharmaceuticals. He graduated from Shanghai Institute of Materia Medica, Chinese Academy of Sciences with PhD in Pharmacology. He received postdoctoral training in Immunology, Neurology, Cell and Gene Therapy at Baylor College of Medicine. Linglong joined Teva in January 2012. In his current role, Linglong oversees immunogenicity assessment activities, including crafting immunogenicity assessment strategy, directing bioanalytical activities, interpreting immunogenicity data, and preparing regulatory filing and correspondence related to immunogenicity. Prior to Teva, he worked at two contract research organizations, including PRACS Institute as the Director of Ligand Binding Laboratory (2010-2011) and Bridge Laboratories as the Director of Immunology (2007-2010), where he directed bioanalytical method development, validation, and sample analysis activities for immunogenicity assessment, pharmacokinetic and pharmacodynamic analyses. From 2001 to 2007 he was Bioanalytical Scientist and Bioassay Group Leader at Tanox, Inc. (now Genentech Inc.) where he established a cell-based assay laboratory and developed assays to support potency and neutralizing antibody testing. He is an active member of American Association of Pharmaceutical Scientists. Over his industry career, he has contributed to approval of several biologics in US or EU markets.

Research Interest

Clinical immunology; bioanalytical method design, development and validation; immunogenicity risk assessment; characterization and interpretation of unwanted immune responses of therapeutic proteins, peptides, and other complex drug products.

Top